Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Navamedic signs deal for Nordic distribution of Re5-NTS

Navamedic has partnered with Re5 ApS for Nordic distribution of Re5-NTS, bringing an innovative treatment option to patients suffering from refractory depression.

Re5 NTS is a non-invasive treatment device based on Danish technology. It was developed in the University of Copenhagen researchers in collaboration with researchers from Karolinska Institutet in Stockholm.

Navamedic CEO Tom Rönnlund said: "The device, which uses technology based on Transcranial Pulsed Electric Fields, has shown very encouraging results in clinical studies. Navamedic sees great value in an unmet, significant medical need for this product, and begins the Nordic roll-out of the device in Denmark to psychiatric clinics.”

According to Navamedic, about 30% of patients with Major Depressive Disorder (MDD) can become refractory. Due to this, optimised standard pharmaceutical and psychological treatment might not provide ample response.

Such patients can continue to face depression even after completing standard treatment and experience a significantly reduced quality of life, reduced daily functioning along with prolonged personal and societal costs.

The Re5-NTS from Navamedic has been designed to be a secondary or complimentary treatment device in conjunction with standard treatment procedure for patients with refractory depression.

The device can be used by patients daily for about half-an hour a day for 8 weeks. Clinical studies noted that patients using the device, complementing with regular treatment can significantly improve his or her situation and also reduce side effects from the combined treatment.

Rönnlund said: "Clinical depression is an incredibly debilitating disease and costs an estimated DKK 4.3bn ($630m) annually, just in the form of treatments and lost productivity, to the Danish society. The disease affects an estimated 3-4% of the population, and up to 30% of them suffer from refractory depression.

“Used as a complementary treatment in combination with standard treatment of refractory depression, the Re5 technology could significantly improve these patients' well-being and quality of life.”